http://medicalxpress.com/ en-us Medical Xpress provides the latest news from American Association for Cancer Research Men who reported sleep problems, including difficulty falling asleep and staying asleep, had up to a twofold increased risk for prostate cancer, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. http://medicalxpress.com/news/2013-05-problems-prostate-cancer.html Cancer Tue, 07 May 2013 00:10:02 EST news287076797 Changes in estrogen breakdown, or metabolism, may be one of the mechanisms by which aerobic exercise lowers a woman's breast cancer risk, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. http://medicalxpress.com/news/2013-05-exercise-related-estrogen-metabolism-breast-cancer.html Cancer Tue, 07 May 2013 00:10:01 EST news287076820 Smoking increased the risk for developing colon cancer, and female smokers may have a greater risk than male smokers, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research. http://medicalxpress.com/news/2013-04-women-smokers-greater-colon-cancer.html Cancer Tue, 30 Apr 2013 13:00:01 EST news286536577 (Medical Xpress)—The engineered antibody MPDL3280A, which targets a protein called programmed death-ligand 1 (PD-L1), was safe and effective for several cancers, according to phase I study results presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-antibody-safety-efficacy-wide-range.html Cancer Wed, 10 Apr 2013 09:50:01 EST news284804550 Researchers have generated new insights into the ways in which physical activity affects how much estrogen is broken down and secreted in the urine of postmenopausal women. These findings enhance understanding of the potential biological mechanisms linking increased physical activity and decreased risk for breast cancer in postmenopausal women, according to the scientist who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-approach-effect-physical-estrogen-metabolism.html Cancer Wed, 10 Apr 2013 09:40:01 EST news284804476 An American Association for Cancer Research (AACR) statement calls on the oncology community to provide evidence-based tobacco cessation treatment for all cancer and cancer-screening patients and to evaluate tobacco as a confounding factor in cancer clinical trial outcomes. The statement was published this morning in Clinical Cancer Research, a journal of the AACR. http://medicalxpress.com/news/2013-04-aacr-policy-guidance-tobacco-cancer.html Cancer Wed, 10 Apr 2013 09:21:05 EST news284804447 Benign disease diagnosis rates after surgery for suspected lung cancer varied widely by state, and the reasons for these variations could inform health policy and clinical guidelines for lung cancer screening, according to a researcher who presented the data at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-prevalence-benign-disease-diagnosis-lung.html Cancer Wed, 10 Apr 2013 09:18:49 EST news284804322 A greater level of toenail selenium was associated with a significant decrease in the risk for advanced prostate cancer, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-cohort-selenium-advanced-prostate-cancer.html Cancer Wed, 10 Apr 2013 08:50:19 EST news284802611 Patients with breast cancer who had a BRCA1 mutation had significantly worse overall and recurrence-free survival rates compared with patients without BRCA mutations, but no evidence for a difference in survival was found between patients with BRCA2 mutations and those without a BRCA mutation, according to data from a large Dutch study presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-patients-brca1-mutations-brca2-poorer.html Cancer Tue, 09 Apr 2013 08:00:01 EST news284710874 Although most survivors of melanoma take precautions to protect their skin from the sun and further occurrences of cancer, data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10, revealed that more than a quarter do not use sunscreen when outside for more than an hour, and more than 2 percent still use tanning beds. http://medicalxpress.com/news/2013-04-melanoma-survivors-tanning-beds-sunscreen.html Cancer Tue, 09 Apr 2013 07:40:03 EST news284710853 Researchers have confirmed that the novel oral agent ARQ 092 inhibits the AKT pathway and has a manageable safety profile in patients with a variety of advanced solid tumors, according to phase I data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-akt-pathway-inhibitor-arq-safety.html Cancer Tue, 09 Apr 2013 07:21:37 EST news284710890 Vemurafenib-resistant tumors in patients with melanoma showed reduced growth after cessation of treatment, and in animal models, drug resistance was prevented by intermittent treatment, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-intermittent-treatment-vemurafenib-lethal-drug.html Cancer Mon, 08 Apr 2013 09:30:01 EST news284629278 Scientists have identified biomarkers that may help predict whether patients with KRAS-mutated non-small cell lung cancer (NSCLC) will respond to concurrent treatment with an MEK inhibitor and a PI3 kinase inhibitor, a drug combination currently being investigated in ongoing clinical trials. The discovery was made as part of a study presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10, by Aaron N. Hata, M.D., Ph.D., a clinical fellow at the Massachusetts General Hospital in Boston. http://medicalxpress.com/news/2013-04-biomarkers-response-drugs-kras-mutated-nsclc.html Cancer Mon, 08 Apr 2013 09:20:08 EST news284629309 A new class of investigational medicines may help to treat patients with cancers driven by mutations in genes such as BRAF or KRAS/NRAS, including those patients who have become resistant to therapies that target BRAF directly, according to preclinical data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-preclinical-potential-inhibitor-drug-resistance.html Cancer Mon, 08 Apr 2013 09:20:04 EST news284629264 The investigational drug AZD5363, which has shown activity in preclinical studies, was well tolerated in humans, and two patients with advanced solid tumors showed partial response, according to data presented at the AACR Annual Meeting 2013, held in Washington, D.C., April 6-10. http://medicalxpress.com/news/2013-04-akt-inhibitor-azd5363-tolerated-yielded.html Cancer Mon, 08 Apr 2013 09:10:01 EST news284629293